Baker Bros. Advisors LP Kodiak Sciences Inc. Transaction History

Baker Bros. Advisors LP

$12.3 Billion
Q3 2025

A detailed history of Baker Bros. Advisors LP transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 17,310,490 shares of KOD stock, worth $338 Million. This represents 2.31% of its overall portfolio holdings.

Number of Shares

17,310,490

Previous 17,310,490 -0.0%

Holding current value

$338 Million

Previous $64.6 Million 338.87%

% of portfolio

2.31%

Previous 0.65%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $6.95 Million - $13.1 Million	1,379,445 Added 8.66%	17,310,490 $132 Million
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $8.86 Million - $112 Million	1,249,741 Added 8.51%	15,931,045 $123 Million
Q3 2021 Nov 15, 2021	BUY	$81.97 - $106.94 $44.5 Million - $58.1 Million	543,423 Added 3.84%	14,681,304 $1.41 Billion
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $19.9 Million - $32.6 Million	257,929 Added 1.86%	14,137,881 $1.31 Billion
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $92.9 Million - $235 Million	1,527,777 Added 12.37%	13,879,952 $2.04 Billion
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $35 Million - $46.1 Million	777,637 Added 6.72%	12,352,175 $731 Million
Q1 2020 May 15, 2020	BUY	$38.18 - $73.95 $20.1 Million - $39 Million	527,249 Added 4.77%	11,574,538 $552 Million
Q4 2019 Feb 14, 2020	BUY	$13.9 - $76.65 $26.4 Million - $146 Million	1,902,173 Added 20.8%	11,047,289 $795 Million
Q3 2019 Nov 14, 2019	BUY	$10.24 - $17.57 $10 - $17	1 Added 0.0%	9,145,116 $132 Million
Q4 2018 Feb 13, 2019	BUY	$6.11 - $10.43 $55.9 Million - $95.4 Million	9,145,115 New	9,145,115 $64.9 Million

Others Institutions Holding KOD

# of Institutions

128

Shares Held

44.4M

Call Options Held

213K

Put Options Held

224K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $1.02B
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Kodiak Sciences Inc. Transaction History